The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback